Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

The FDA approves lamivudine for the treatment of chronic HBV

Dec. 10, 1998

In vitro and clinical study results support development of nitazoxanide for H. pylori infection

Dec. 10, 1998

Eisai begins product launch of proton pump inhibitor in Germany

Dec. 8, 1998

Six-month treatment with ciprofloxacin improves response rate in ulcerative colitis

Dec. 4, 1998

Agents for ulcers synthesized and evaluated at Shiseido

Dec. 3, 1998

AxyS initiates phase I studies of APC-2059 for treatment of acute inflammatory bowel disease

Dec. 3, 1998

Lead SelCID compound poised to enter phase II clinical trials for Crohn's disease

Dec. 2, 1998

Health Canada approves lamivudine for treatment of chronic HBV

Dec. 2, 1998

AMBI seeks partners to develop oral nisin for H. pylori eradication

Dec. 2, 1998

Multiple clinical studies support efficacy and safety of HSR-237 in patients with IBS

Nov. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...